Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.53 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20762032 | 0.98 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1MBTD1KDM4ESMN1; SMN2 | |
| SCHEMBL21482489 | 0.85 | POLB (0.57) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL23334495 | 0.85 | POLB (0.57) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL20762545 | 0.82 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL12967015 | 0.82 | MAPK1 (0.70) | L3MBTL1KDM4ESMN1; SMN2MAPK1ALDH1A1 | |
| SCHEMBL19562730 | 0.82 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1MBTD1KDM4ESMN1; SMN2 | |
| SCHEMBL6581926 | 0.82 | CHRM1 (0.51) | L3MBTL3L3MBTL1MBTD1KDM4ESMN1; SMN2 | |
| SCHEMBL25074931 | 0.81 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1MBTD1KDM4ETP53BP1 | |
| SCHEMBL24848610 | 0.81 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1MBTD1KDM4ETP53BP1 | |
| SCHEMBL3160275 | 0.81 | HPGD (0.65) | L3MBTL3L3MBTL1MBTD1SMN1; SMN2TP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | JIANGSU YAHONG MEDITECH CO., LTD. (CN) | 2024-11-26 | — | — | US | disclosed |
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024073624-A2 | ANTIPROLIFERATIVE BETTI BASES AND PRODRUGS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023137026-A1 | CAMPTOTHECIN ANALOGS CONJUGATED TO A GLUTAMINE RESIDUE IN A PROTEIN, AND THEIR USE | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134465-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF AND USE THEREOF | 上海艾力斯医药科技股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023115167-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20230158154-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | TUBULIS GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| WO-2023274246-A1 | AMIDE COMPOUND AND USE THEREOF | 成都分迪药业有限公司 | 2023-01-05 | — | — | WO | disclosed |
| US-20220409612-A1 | TREATMENT OF CANCER | ELLIPSES PHARMA LTD (GB) | 2022-12-29 | — | — | US | disclosed |
| US-7794747-B2 | Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes | MEDIGENE ONCOLOGY GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-7794747-B2 | Stabilization, homogenizing, sterile filtration, dehydration, reconstitution, ultrafiltration; storage stability; taxanes | MEDIGENE ONCOLOGY GMBH (DE) | 2010-09-14 | — | — | US | disclosed |
| US-20100178243-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | MEDIGENE AG (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100178243-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | MEDIGENE AG (DE) | 2010-07-15 | — | — | US | disclosed |
| EP-1553923-B1 | CAMPTOTHECIN-CARBOXYLATE FORMULATIONS | MEDIGENE AG (DE) | 2009-09-09 | — | — | EP | disclosed |
| CN-101314587-A | Preparation for midbody of Irinotecan and preparation for Irinotecan | SHANGHAI HENGHE MEDICAL TECHNO (CN) | 2008-12-03 | — | — | CN | disclosed |
| US-20070148250-A1 | Loading of a camptothecin drug into colloidal nanoparticles | MEDIGENE AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070148221-A1 | Method of producing lipid complexed camptothecin-carboxylate | MEDIGENE AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070148221-A1 | Method of producing lipid complexed camptothecin-carboxylate | MEDIGENE AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070148250-A1 | Loading of a camptothecin drug into colloidal nanoparticles | MEDIGENE AG (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152048-B2 | Nitroxoline prodrug and use thereof | NOS1, NOS2, NNT | L3MBTL3 4074/4885L3MBTL1 3303/4885MBTD1 2472/4885 |
| US-20070148250-A1 | Loading of a camptothecin drug into colloidal nanoparticles | KIT, TYMP, TOP1 | L3MBTL3 4030/4885L3MBTL1 4126/4885MBTD1 3981/4885 |
| US-20070148221-A1 | Method of producing lipid complexed camptothecin-carboxylate | LIPA, PCTP, TTPA | L3MBTL3 3461/4885L3MBTL1 3235/4885MBTD1 2637/4885 |
| US-20220409612-A1 | TREATMENT OF CANCER | DDX1, CDC73, CBX2 | L3MBTL3 2749/4885L3MBTL1 1874/4885MBTD1 3450/4885 |
| US-20230158154-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | CALCR, PTH1R, BCR | L3MBTL3 4493/4885L3MBTL1 4501/4885MBTD1 2384/4885 |
| US-20100178243-A1 | Novel method of stabilizing diagnostic and therapeutic compounds in a cationic carrier system | SLC7A1, NPC1L1, LIPA | L3MBTL3 1273/4885L3MBTL1 868/4885MBTD1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.